Literature DB >> 21508933

Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis.

Camilo de la Fuente-Sandoval1, Pablo León-Ortiz, Rafael Favila, Sylvana Stephano, David Mamo, Jesús Ramírez-Bermúdez, Ariel Graff-Guerrero.   

Abstract

The glutamatergic and dopaminergic systems are thought to be involved in the pathophysiology of schizophrenia. Their interaction has been widely documented and may have a role in the neurobiological basis of the disease. The aim of this study was to compare, using proton magnetic resonance spectroscopy ((1)H-MRS), glutamate levels in the precommissural dorsal-caudate (a dopamine-rich region) and the cerebellar cortex (negligible for dopamine) in the following: (1) 18 antipsychotic-naïve subjects with prodromal symptoms and considered to be at ultra high-risk for schizophrenia (UHR), (2) 18 antipsychotic-naïve first- episode psychosis patients (FEP), and (3) 40 age- and sex- matched healthy controls. All subjects underwent a (1)H-MRS study using a 3Tesla scanner. Glutamate levels were quantified and corrected for the proportion of cerebrospinal fluid and percentage of gray matter in the voxel. The UHR and FEP groups showed higher levels of glutamate than controls, without differences between UHR and FEP. In the cerebellum, no differences were seen between the three groups. The higher glutamate level in the precommissural dorsal-caudate and not in the cerebellum of UHR and FEP suggests that a high glutamate level (a) precedes the onset of schizophrenia, and (b) is present in a dopamine-rich region previously implicated in the pathophysiology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21508933      PMCID: PMC3154101          DOI: 10.1038/npp.2011.65

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  98 in total

1.  Regional gray matter volume abnormalities in the at risk mental state.

Authors:  Stefan J Borgwardt; Anita Riecher-Rössler; Paola Dazzan; Xavier Chitnis; Jacqueline Aston; Margret Drewe; Ute Gschwandtner; Sven Haller; Marlon Pflüger; Evelyne Rechsteiner; Marcus D'Souza; Rolf-Dieter Stieglitz; Ernst-Wilhelm Radü; Philip K McGuire
Journal:  Biol Psychiatry       Date:  2006-11-13       Impact factor: 13.382

2.  Proton magnetic resonance spectroscopy (1H-MRS) of the cerebellum in men with schizophrenia.

Authors:  P Tibbo; C C Hanstock; S Asghar; P Silverstone; P S Allen
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

3.  Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study.

Authors:  Ludger Tebartz van Elst; Gabi Valerius; Martin Büchert; Thorsten Thiel; Nicholas Rüsch; Emanuel Bubl; Jürgen Hennig; Dieter Ebert; Hans M Olbrich
Journal:  Biol Psychiatry       Date:  2005-07-14       Impact factor: 13.382

Review 4.  Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of "intact" animals.

Authors:  Hélène N David; Marc Ansseau; Jacques H Abraini
Journal:  Brain Res Brain Res Rev       Date:  2005-11-08

5.  Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients?

Authors:  Victoria Villalta-Gil; Míriam Vilaplana; Susana Ochoa; Josep Maria Haro; Montserrat Dolz; Judit Usall; Jorge Cervilla
Journal:  Schizophr Res       Date:  2006-07-21       Impact factor: 4.939

6.  Assessment of glutamate and glutamine contribution to in vivo N-acetylaspartate quantification in human brain by (1)H-magnetic resonance spectroscopy.

Authors:  Valeria Clementi; Caterina Tonon; Raffaele Lodi; Emil Malucelli; Bruno Barbiroli; Stefano Iotti
Journal:  Magn Reson Med       Date:  2005-12       Impact factor: 4.668

7.  Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia.

Authors:  Siew E Chua; Charlton Cheung; Vinci Cheung; Jack T K Tsang; Eric Y H Chen; Jason C H Wong; Jason P Y Cheung; Lawrance Yip; Kin-Shing Tai; John Suckling; Gráinne M McAlonan
Journal:  Schizophr Res       Date:  2006-11-13       Impact factor: 4.939

8.  Regionally specific alterations in membrane phospholipids in children with ADHD: An in vivo 31P spectroscopy study.

Authors:  Jeffrey A Stanley; Heidi Kipp; Erika Greisenegger; Frank P MacMaster; K Panchalingam; Jay W Pettegrew; Matcheri S Keshavan; Oscar G Bukstein
Journal:  Psychiatry Res       Date:  2006-11-07       Impact factor: 3.222

Review 9.  What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update.

Authors:  Christopher Abbott; Juan Bustillo
Journal:  Curr Opin Psychiatry       Date:  2006-03       Impact factor: 4.741

Review 10.  Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.

Authors:  Daniel C Javitt
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

View more
  102 in total

1.  Comment regarding increased striatal glutamate in schizophrenia.

Authors:  Richard J Maddock; Michael H Buonocore
Journal:  Neuropsychopharmacology       Date:  2012-03       Impact factor: 7.853

2.  A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia.

Authors:  Meredith A Reid; David M White; Nina V Kraguljac; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2015-12-21       Impact factor: 4.939

Review 3.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

4.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Authors:  Tatsunobu Natsubori; Hideyuki Inoue; Osamu Abe; Yosuke Takano; Norichika Iwashiro; Yuta Aoki; Shinsuke Koike; Noriaki Yahata; Masaki Katsura; Wataru Gonoi; Hiroki Sasaki; Hidemasa Takao; Kiyoto Kasai; Hidenori Yamasue
Journal:  Schizophr Bull       Date:  2013-09-10       Impact factor: 9.306

5.  Nicotine-induced activation of caudate and anterior cingulate cortex in response to errors in schizophrenia.

Authors:  Lauren V Moran; Luke E Stoeckel; Kristina Wang; Carolyn E Caine; Rosemond Villafuerte; Vanessa Calderon; Justin T Baker; Dost Ongur; Amy C Janes; A Eden Evins; Diego A Pizzagalli
Journal:  Psychopharmacology (Berl)       Date:  2017-11-27       Impact factor: 4.530

6.  Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity.

Authors:  Eric Plitman; Raihaan Patel; Jun Ku Chung; Jon Pipitone; Sofia Chavez; Francisco Reyes-Madrigal; Gladys Gómez-Cruz; Pablo León-Ortiz; M Mallar Chakravarty; Camilo de la Fuente-Sandoval; Ariel Graff-Guerrero
Journal:  Neuropsychopharmacology       Date:  2016-06-08       Impact factor: 7.853

7.  Interactions between glutamate, dopamine, and the neuronal signature of response inhibition in the human striatum.

Authors:  Robert C Lorenz; Tobias Gleich; Ralph Buchert; Florian Schlagenhauf; Simone Kühn; Jürgen Gallinat
Journal:  Hum Brain Mapp       Date:  2015-07-14       Impact factor: 5.038

8.  Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study.

Authors:  Jee In Kang; Hae-Jeong Park; Se Joo Kim; Kyung Ran Kim; Su Young Lee; Eun Lee; Suk Kyoon An; Jun Soo Kwon; Jong Doo Lee
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

9.  Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.

Authors:  Scott A Schobel; Nashid H Chaudhury; Usman A Khan; Beatriz Paniagua; Martin A Styner; Iris Asllani; Benjamin P Inbar; Cheryl M Corcoran; Jeffrey A Lieberman; Holly Moore; Scott A Small
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

10.  Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL study.

Authors:  S Andrea Wijtenburg; Susan N Wright; Stephanie A Korenic; Frank E Gaston; Nkemdilim Ndubuizu; Joshua Chiappelli; Robert P McMahon; Hongji Chen; Anya Savransky; Xiaoming Du; Danny J J Wang; Peter Kochunov; L Elliot Hong; Laura M Rowland
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.